University of California, Los Angeles (UCLA), Health Sciences

ACTG Launches Clinical Trial Testing Treatment for COVID-19

Study will Evaluate Hydroxychloroquine+Azithromycin among Adults with Mild to Moderate COVID-19 in the United States

 

Newswise — Los Angeles, Calif. – The AIDS Clinical Trials Group (ACTG), the world’s largest and longest established HIV research network, today announced the initiation of ACTG 5395, a clinical trial to evaluate whether the drug combination hydroxychloroquine and azithromycin can prevent hospitalization and death from COVID-19 (which is caused by infection with the virus SARS-CoV-2). There is currently no approved vaccine or therapeutic to prevent or treat COVID-19, which has been spreading worldwide since cases were first reported in December 2019 in Wuhan, Hubei Province, China. For information about enrolling in the trial, please email actg.communications@fstrf.org

“There is an urgent public health need to rapidly evaluate interventions to treat COVID-19, which has emerged as a global pandemic in recent months,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles. “Well-designed trials are needed to evaluate whether drugs that have been studied and used over many years to treat other conditions are effective against COVID-19. ACTG’s history of implementing a wide variety of clinical trials over the last 33 years positions us well to quickly execute this clinical trial and help determine whether hydroxychloroquine and azithromycin may be an effective treatment for COVID-19.” 

ACTG is conducting this double-blind, placebo-controlled, randomized phase 2b clinical trial at 31 of its U.S.-based sites (the list can be accessed here) and will enroll approximately 2,000 adults with COVID-19. The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, which also funds the ACTG. Participants will be randomized to orally receive one of two regimens. The first arm will receive a loading dose of hydroxychloroquine (400 mg twice a day on the first day), followed by 200 mg twice a day for six days, plus 500 mg of azithromycin on the first day, followed by 250 mg every day for four days. The second arm will receive matching placebos.

In order to qualify for the study, participants must have tested positive for SARS-CoV-2 infection in the outpatient setting and be experiencing at least one of the following symptoms: fever, cough, or shortness of breath. Eligible participants include people living with HIV, women who are pregnant, and those currently breastfeeding.

ACTG 5395 is being led by protocol chair Davey Smith, M.D. of the University of California, San Diego, along with David Wohl, M.D. of the University of North Carolina and Kara W. Chew M.D., M.S. and Eric S. Daar, M.D. of the University of California, Los Angeles.  

“Because the COVID-19 pandemic has been particularly devastating for people who are older and have underlying health issues, it is our goal that at least half of study participants will be members of these high-risk groups,” said Dr. Smith. “By ensuring meaningful representation of individuals who are 60 years and older or immunocompromised and those with chronic lung, kidney, and liver disease, severe obesity, hypertension, or diabetes, we are hopeful that we will gain important insights that will directly impact care for people with COVID-19.” 

As of May 14, 2020, the World Health Organization (WHO) has reported 4,218,212 cases and 290,242 related deaths worldwide. The United States became the epicenter of the epidemic on March 26, 2020, reporting more cases than any other country worldwide. As of May 13, 2020, the Centers for Disease Control and Prevention (CDC) has reported 1,364,061 cases and 82,246 related deaths in the United States. 

Hydroxychloroquine is currently approved for malaria treatment and prevention, as well as for the treatment of autoimmune conditions, including rheumatoid arthritis and lupus. Azithromycin is currently approved to treat bacterial infections, including sinusitis, community-acquired pneumonia, urethritis/cervicitis, pharyngitis, and acute exacerbations of COPD. While there has been some evidence that this drug combination may decrease viral loads among people with COVID-19, large, well-controlled clinical trials are needed to determine its true efficacy. The ACTG, with its ability to use existing sites and staff to rapidly conduct trials, is ideally positioned to conduct a major clinical trial among patients with COVID-19 (who currently have no proven treatment options) during this pandemic. 

For more information about ACTG 5395, visit www.actgnetwork.org or ClinicalTrials.gov using study identifier NCT04358068.

 

About the AIDS Clinical Trials Group

Founded in 1987, the AIDS Clinical Trials Group (ACTG) is the world’s largest and longest established HIV research network. The ACTG conducts groundbreaking studies to improve the treatment of HIV and its complications, reduce new infections and HIV-related illness, and advance new approaches to prevent, treat, and ultimately cure HIV in adults and children. ACTG investigators and research units in 12 countries serve as major resources for HIV/AIDS research, treatment, care, and training/education in their communities. ACTG studies have helped establish current paradigms for managing HIV disease, and have informed HIV treatment guidelines, resulting in dramatic decreases in HIV-related mortality worldwide.

 

 

# # #

 

 




Filters close

Showing results

110 of 2054
Released: 2-Jun-2020 1:55 PM EDT
Research Affiliates CEO on Leading and Investing in a Time of Uncertainty
University of Virginia Darden School of Business

As CEO of global asset management firm Research Affiliates, Katrina Sherrerd (Ph.D. ’87) is leading the influential financial services firm through a period of deep global uncertainty, as world financial markets continue to show great volatility amid the coronavirus pandemic.

Newswise: Studying pandemic's effects on sexual health and well-being
Released: 2-Jun-2020 1:50 PM EDT
Studying pandemic's effects on sexual health and well-being
Indiana University

One in five adults in the United States report they have experienced change – mostly a decrease – in their sexual behavior during the early months of the COVID-19 pandemic, according to a new study by Indiana University researchers.

Newswise: HarrisJared-fac-profile.jpg?itok=pQ8OjWkt
Released: 2-Jun-2020 1:50 PM EDT
Keys to Small Business Resilience in Uncertain Times
University of Virginia Darden School of Business

Faced with limited customer flow, forced shut down of operations and a looming economic recession, the uncertainty of the COVID-19 pandemic leaves small-business owners to make decisions with little idea of what the future may hold. What lessons can they take from the success and resiliency of businesses that have survived crises in the past?

Released: 2-Jun-2020 1:05 PM EDT
Suppression of COVID-19 spread is possible, suggests new model
Washington University in St. Louis

Suppression of the spread of COVID-19 is an attainable goal, and it can be done through strategies that ease social distancing guidelines, suggests a new model developed by researchers at Washington University in St. Louis and the Brookings Institution.

Newswise: COVID-19 Pandemic Highlights Advantages of Digital Technology in Clinical Research
Released: 2-Jun-2020 11:05 AM EDT
COVID-19 Pandemic Highlights Advantages of Digital Technology in Clinical Research
Osteopathic Research Center, University of North Texas Health Science Center

Digital technology has facilitated continued research operations for a pain research registry during the COVID-19 pandemic. Cloud-based systems that allow remote management of research studies and collection of data may signal a new trend for future clinical research endeavors.

Released: 2-Jun-2020 10:25 AM EDT
Pediatric injuries in the home are on the rise
University of Texas Health Science Center at Houston

COVID-19 has changed the way families go about their daily routines. With public schools being closed, most parents now have to take on several roles at once. Most are working, providing home schooling and care during the day, and taking on other new roles.

access_time Embargo lifts in 2 days
Embargo will expire: 9-Jun-2020 11:00 AM EDT Released to reporters: 2-Jun-2020 10:25 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 9-Jun-2020 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Psychologist shares quick relief for parents struggling with child behavior during COVID-19 pandemic
Released: 2-Jun-2020 9:50 AM EDT
Psychologist shares quick relief for parents struggling with child behavior during COVID-19 pandemic
West Virginia University - Eberly College of Arts and Sciences

Nonstop family time during the COVID-19 pandemic has magnified challenges for parents caring for young children around the clock. Using research-backed therapies that she helped pioneer, a WVU psychology professor has quick relief strategies for parents struggling with child misbehavior during the lockdown.


Showing results

110 of 2054

close
1.74439